Monitoring product safety in the postmarketing environment

Therapeutic Advances in Drug Safety

Volumn 4, Issue 5, 2013, Pages 211-219

  Sharrar, Robert g ^a   Dieck, Gretchen s ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

pharmacovigilance; product safety; signal detection

Indexed keywords

NATALIZUMAB; SILDENAFIL; TADALAFIL; VARDENAFIL;

ANAPHYLACTIC SHOCK; ANAPHYLAXIS; CONSUMER; DATA BASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; ENVIRONMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; LABORATORY TEST; LAWYER; MEDICAL LITERATURE; OBSERVATIONAL STUDY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT;

EID: 84890160471     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098613490780     Document Type: Review

References (27)

1. Bate A. Lindquist M. Edwards I. Olsson S. Orre R. Lansner A. (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54: 315–321.
2. Centers for Disease Control and Prevention (CDC) (2012) Poliomyelitis. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 12th edn, 2nd printing. Atlanta, GA: CDC.
3. DeStefano F. Verstraeten T. Chen R. (2002) Hepatitis B vaccine and risk of multiple sclerosis. Expert Rev Vaccines 1: 461–466.
4. Dieck G. Sharrar R. (2013) Preparing for safety issues following drug approval: preapproval risk management considerations. Submitted to Therapeutic Advances in Drug Safety.
5. DuMouchel W. (1999) Bayesian data mining in large frequency tables, with an application to the FDA reporting system. Am Stat 53: 177–202.
6. European Medicines Agency (EMEA) (2008) Guideline on the use of statistical detection methods in the EuraVigilance Data Analysis System. Doc. Ref. EMEA/106464/2006rev.1. London: EMEA.
7. European Parliament and Council of the European Union, Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use, Off J Eur Union, (2010), L348, 74-99
8. European Parliament and Council of the European Union, Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products, Off J Eur Union, (2010), 3L98, 1-16
9. Evans S. Waller P. Davis S. (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10: 483–486.
10. Faich G. Morris J. (2012) Adverse reaction signaling and disproportionality analysis: an update. Drug Inf J 46: 708–714.
11. Food and Drug Administration (FDA) (2011a) Adverse Event Reporting System (AERS) statistics (31 December 2011). Washington DC: FDA. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070093.htm [ accessed 21 March 2012].
12. Food and Drug Administration (FDA) (2011b) Mini-Sentinel. Mini-Sentinel Distributed Database ‘At a Glance– as of 31 December 2011. Washington DC: FDA. Available at: http://mini-sentinel.org/about_us/MSDD_At-a-Glance.aspx [ accessed 20 June 2012].
13. Food and Drug Administration (FDA) (2011c) Report to Congress. The Sentinel Initiative – a national strategy for monitoring medical product safety. Washington DC: FDA.
14. Food and Drug Administration (FDA) (2012) Periodic benefit–risk evaluation report (PBRER) E2C (R2). Step 2 version dated 1 February 2012. Washington DC: FDA.
15. Heads of Medicines Agency (HMA) and European Medicines Agency (EMEA) (2012a) Guideline on good pharmacovigilance practices (GVP). Annex I – Definitions. Doc. Ref. EMA/876333/2011. London: EMEA.
16. Heads of Medicines Agency (HMA) and European Medicines Agency (EMEA) (2012b) Guideline on good pharmacovigilance practices (GVP). Module V – Risk management systems. Doc. Ref. EMA/838713/2011. London: EMEA.
17. Heads of Medicines (HMA) and European Medicine Agency (EMEA) (2012c) Guideline on good pharmacovigilance practices (GVP). Module VII – Periodic safety update report. Doc. Ref. EMA/816292/2011. London: EMEA.
18. Heads of Medicines (HMA) and European Medicine Agency (EMEA) (2012d) Guideline on good pharmacovigilance practices (GVP). Module VIII – Post-authorization safety studies. Doc. Ref. EMA/813938/2011. London: EMEA.
19. Heads of Medicines Agency (HMA) and European Medicines Agency (EMEA) (2012e) Guideline on good pharmacovigilance practices (GVP). Module IX – Signal management. Doc. Ref. EMA/827661/2011. London: EMEA.
20. International Conference on Harmonisation. (2012) (ICH) E2C (R2) Periodic Benefit-Risk Evaluation Report. Current Step 4 version, dated 17 December 2012. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2C/E2C_R2_Step4.pdf (accessed 15 May 2013).
21. Observational Medical Outcomes Partnership (OMOP) (2009) Observational Medical Outcomes Partnership [online]. Bethesda, MD: Foundation of the National Institutes of Health. Available at http://omop.fnih.org/node/22 (accessed 20 June 2012).
22. Observational Medical Outcomes Partnership (OMOP) (2012) OMOP 2012 research [online]. Bethesda, MD: Foundation of the National Institutes of Health. Available at http://omop.fnih.org/Research (accessed 17 March 2013).
23. Platt R. Carnahan R. (eds) (2012) Supplement: The U.S. Food and Drug Administration–s Mini-Sentinel Program. Pharmacoepidemiol Drug Saf 21(Suppl. S1): 1–303.
24. Sharrar R. LaRussa P. Galea S. Steinberg S. Sweet A. Keatley M. (2001) The postmarketing safety profile of varicella vaccine. Vaccine 19: 916–923.
25. Stang P. Ryan P. Racoosin J. Overhage J. Hartzema A. Reich C. (2010) Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 153: 600–606.
26. Vaccine Adverse Event Reporting System (VAERS) (2013) VAERS data 13 Feb 2013 [online]. Rockville, MD: VAERS. Available at http://vaers.hhs.gov/data/data [ accessed 18 March 2013].
27. WHO Uppsala Monitoring Centre (2012) Reporting trends [online]. Uppsala, Sweden: Uppsala Monitoring Centre. Available at: http://www.who-umc.org/DynPage.aspx?id=108476&mn1=7347&mn2=7252&mn3=7322&mn4=7558 (accessed on 18 March 2013).